CurrentCentenePolicy CP MP.121

Homocysteine Testing

Defines medical necessity and coverage stance for homocysteine laboratory testing for members of Centene-affiliated health plans, including indications considered medically necessary and indications where testing has not been proven to improve outcomes.

Policy Summary

PayerCentene

PolicyHomocysteine Testing

Policy CodePolicy CP MP.121

Change TypeNo material change

Effective Date

Next Review Date

Key ActionOrder homocysteine testing only for suspected homocystinuria due to cystathionine beta-synthase deficiency and document the supporting diagnosis (e.g., E72.11).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CPT 83090Procedure code

E72.11Supporting ICD-10

5-15Reference range

>100Severe threshold

Coverage Criteria

inv-01: Medically necessary — Covered when ALL of the following are met:

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-02: Not proven to improve outcomes / Investigational — lists indications considered not proven to improve outcomes

Not proven to improve outcomes for any of the following (policy states these indications have not been proven to improve outcomes compared to other technologies):

Unsupported indications: Cardiovascular risk testing; idiopathic (unprovoked) venous thromboembolism, recurrent venous thromboembolism, thrombosis occurring at ≤45 years of age, or thrombosis at an unusual site; borderline low or inconclusive vitamin B12 deficiency (without additional supporting evidence); and all other non-homocystinuria conditions.

Policy states these uses have not been proven to improve outcomes.

All indications for homocysteine testing that are not explicitly listed as medically necessary in this policy are considered not proven to improve outcomes compared to other diagnostic technologies. The policy identifies a single medically necessary indication (diagnosis of homocystinuria due to cystathionine beta-synthase deficiency); testing outside that indication lacks evidence of outcome benefit and may be denied.

Examples of uses that the policy considers not proven to improve outcomes include: cardiovascular risk assessment; evaluation of idiopathic (unprovoked) venous thromboembolism, recurrent VTE, thrombosis occurring at ≤45 years of age, or thrombosis at an unusual site; and use for borderline or inconclusive vitamin B12 deficiency (without additional supporting evidence). The policy also states that testing for all other non-homocystinuria conditions is not supported as improving outcomes.

Covered Indications

inv-15: Diagnosis of homocystinuria due to cystathionine beta-synthase deficiency — supported by ICD-10 codes such as E72.11

Diagnosis supporting coverage: Diagnosis of homocystinuria due to cystathionine beta-synthase deficiency.

Supported ICD-10 codes include E72.11 (Homocystinuria); related codes E72.10 and E72.19 are listed as supporting codes.

Provider Actions and Documentation

Denial Risk

Potential denial for unsupported indications

Homocysteine testing (including CPT 83090) may be denied when ordered for indications that are not supported by evidence of improved clinical outcomes. Tests for cardiovascular risk assessment, screening for venous thromboembolism (including idiopathic or recurrent VTE, thrombosis at age >45, or thrombosis at unusual sites), borderline vitamin B12 deficiency evaluation, or for other unspecified/unsupported conditions are considered not proven to improve outcomes and may be denied.

Affected codes: CPT 83090 (homocysteine, total)
Unsupported indications: cardiovascular risk testing; idiopathic/recurrent VTE or VTE at age >45 or uncommon sites; borderline B12 deficiency; other unproven indications

Documentation Required

Clinical management context and required documentation

Document the clinical management context when ordering homocysteine testing. Include the suspected or confirmed diagnosis (e.g., homocystinuria due to cystathionine beta‑synthase deficiency), relevant signs/symptoms, prior test results, and how the test result will affect patient management (treatment decisions or referrals). Note that homocysteine levels are affected by vitamin B6, B12, and folate status; testing may be appropriate to evaluate suspected homocystinuria or to guide management when a diagnosis consistent with coverage criteria is documented.

Document diagnosis code consistent with coverage (see ICD-10 codes supporting coverage)
Record prior therapy or supplementation (folate, B6, B12) and any prior relevant laboratory results
State how results will change treatment (e.g., confirm homocystinuria for targeted therapy)

Documentation Required

Documentation must support the diagnosis and coverage criteria

Order requests should be supported by documentation that aligns with the coverage criteria and diagnosis codes (e.g., E72.11 Homocystinuria). When the medical record does not support the diagnosis or clinical rationale consistent with policy criteria, the request may be denied.

Ensure the chart contains problem list/diagnosis, clinical notes justifying test, and any prior relevant labs or genetic testing results

Not Covered / Investigational

Not covered: homocysteine testing when ordered for cardiovascular risk assessment; for evaluation of idiopathic or recurrent venous thromboembolism including thrombosis at ≤45 years or at an unusual site; for the assessment of borderline or inconclusive vitamin B12 deficiency lacking corroborating evidence; and for other non-homocystinuria indications. These indications have not been demonstrated to improve clinical outcomes compared with other technologies and therefore are considered unsupported.

Ordering Requirements

Note

Ordering requirements and documentation of medical necessity

There are no explicit ordering‑provider restrictions in the policy; however, providers must exercise professional judgment and document medical necessity consistent with the coverage criteria when ordering testing.

Definitions

Homocystinuria — definition and clinical description

DefinitionA rare inherited condition characterized by severe elevations in plasma and urine homocysteine, frequently due to cystathionine beta-synthase (cystathionine-B-synthase) deficiency.

PathophysiologyMutations in enzymes of homocysteine metabolism (eg, cystathionine beta-synthase) impair transsulfuration and lead to accumulation of homocysteine.

Clinical significanceAssociated with premature thrombotic events and increased thrombotic risk.

Homocysteine level categories

Basal5–15 µmol/L

Moderate15–30 µmol/L

Intermediate30–100 µmol/L

Severe>100 µmol/L

Background

Homocysteine is an intermediary amino acid in the methionine-to-cysteine metabolic pathway. Severe elevations are characteristic of homocystinuria, most commonly due to cystathionine beta-synthase deficiency, and are associated with an increased thrombotic risk. B‑vitamin status (folate, vitamin B6, vitamin B12) influences plasma homocysteine concentrations; supplementation lowers homocysteine levels, but randomized trials have not consistently shown reductions in cardiovascular events from homocysteine lowering. Reference concentration categories are: basal 5–15 µmol/L; moderate 15–30 µmol/L; intermediate 30–100 µmol/L; severe >100 µmol/L.